PFE Jan 2025 50.000 call
| Previous close | 0.0400 |
| Open | 0.0400 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 50.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0400 - 0.0400 |
| Contract range | N/A |
| Volume | |
| Open interest | 19.04k |
- Investing.com
Intel, Pfizer, Trump Media and Target rise premarket; Apple falls
Investing.com -- U.S. stock futures edged largely higher Monday, with traders cautious ahead of the latest Federal Reserve policy-setting meeting.
Business WirePfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
NEW YORK, September 14, 2024--Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia and elevated levels of GDF-15. Cachexia is a common, life-threatening wasting condition that can significantly impact quality of life in affected patients with cancer.ii,iii Results will be presented
Business WirePfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
NEW YORK, September 14, 2024--Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC). After an additional 18 months of follow-up, the objective response rate (ORR) and the median duration of response (DoR) as assessed by independent radiology revie
